CRL Resubmission: Class 1 vs Class 2, Timelines, and Odds

You bought a biotech ahead of its PDUFA date. The FDA came back with a Complete Response Letter (CRL), and the stock gapped down 30% before you could react. Now you are holding a position down a third and asking the one question every biotech trader eventually faces: do you sell, hold, or buy more?

The solution: a CRL is not a death sentence, but it is a fork in the road. Your entire decision hinges on one thing: why the FDA rejected the drug, and which resubmission bucket it lands in. Here is the five-step playbook.

Step 1: Read the CRL and classify the deficiency

A CRL is a letter telling you the FDA will not approve the drug in its current form, and it always lists the specific deficiencies. Your first job is to sort them into one of two buckets:

• CMC / manufacturing deficiencies: problems with how the drug is made (chemistry, manufacturing, and controls). These are usually fixable with time and money.
• Efficacy / safety deficiencies: the FDA is not convinced the drug works or is safe enough. These are far harder to fix and often require a brand new trial.

The distinction matters more than anything else in this playbook. A manufacturing CRL is an inconvenience. An efficacy CRL is often the beginning of the end. If you are unsure what a CRL is, start with what a complete response letter actually means.

Red flag: a CRL that demands a new clinical trial. That resets your timeline by years and your odds by a lot.

Step 2: Figure out Class 1 vs Class 2

When the company resubmits, the FDA classifies the resubmission as Class 1 or Class 2, and that classification sets the review clock:

• Class 1 resubmission: minor fixes like labeling changes, a facility correction, or straightforward CMC updates. The FDA reviews it in 2 months.
• Class 2 resubmission: major responses like new clinical data or a substantial safety answer. The FDA reviews it in 6 months.

The rule of thumb: CMC-only fixes usually land as Class 1. Anything touching efficacy or safety lands as Class 2. A Class 1 classification means the company thinks it can be approved in about two months. A Class 2 means another half-year of waiting. The FDA’s own process manual spells out the 2-month and 6-month review clocks.

Step 3: Map the real timeline

Add up the clock so you know how long you are actually holding:

1. CRL received (stock gaps down).
2. Company requests a Type A meeting with the FDA to agree on the path back, typically within 30 days.
3. Company resubmits, usually 2 to 6 months after the CRL.
4. FDA classifies the resubmission Class 1 or Class 2 and sets a new goal date.
5. Decision lands 2 months (Class 1) or 6 months (Class 2) after resubmission.

A Class 2 resubmission after a slow fix can mean 8 to 12 months from CRL to final decision. A Class 1 with a fast fix can resolve in 3 to 4 months. That gap is dead-money time: the stock trades sideways with no news, and you are paying to hold it.

Step 4: Recalculate your odds honestly

Here is the number that should reset your expectations: across the 2018 to 2022 PDUFA cycles, 37% of NDAs and BLAs received a CRL. Roughly one in three applications gets rejected, so a CRL is common rather than exceptional. But your odds after a CRL depend entirely on the deficiency:

• CMC / manufacturing CRLs have the best resubmission odds. The drug was already judged safe and effective; only the factory needs work.
• Efficacy CRLs are the worst. The FDA is saying “prove it works,” which usually means a new trial and years of additional risk.

Three red flags that tank your odds:

1. A third CRL. If the same drug has been rejected twice already, the pattern is the problem. Elevar’s rivoceranib got its third CRL in July 2026 on manufacturing deficiencies, even though the drug was already approved in China. Third CRLs rarely end well.
2. An advisory committee that voted no. If outside experts rejected the drug before the CRL even landed, the resubmission is fighting uphill.
3. Efficacy-driven deficiencies. The FDA questioning whether the drug works is the hardest objection to overcome.

You can browse the full history of rejection letters on the FDA’s CRL table.

Step 5: Trade the pattern, not the prediction

The CRL-to-resubmission trade follows a predictable rhythm:

1. The gap-down. The stock drops 30% to 60% on the CRL, often on heavy volume as catalyst traders bail.
2. Dead-money consolidation. The stock trades in a range with no news for weeks or months while the company works the response.
3. The run-up. As the new PDUFA date approaches, the stock often rallies 15% to 40% as traders position for approval.

The temptation is to buy the gap-down. The discipline is to wait. The gap-down day is usually not the bottom; it is the first repricing in a process that takes months. If you want to play it, wait for the resubmission classification. A Class 1 classification is the first concrete signal that the fix is minor and the odds improved.

Common mistakes

• Buying the gap-down “because it’s cheap.” You are catching a falling knife. The deficiency is not fixed just because the stock is down 40%.
• Assuming every CRL is recoverable. Efficacy CRLs are a different animal from CMC CRLs. Most CRLs that demand new trials never produce an approved drug.
• Holding through the resubmission without a plan. Decide your exit before the new PDUFA date arrives. A Class 2 resubmission means signing up for another six months of binary risk.
• Ignoring the classification letter. The Class 1 vs Class 2 determination is public and it is the single most informative signal about your odds. Read it.

Final checklist

• Read the CRL and classify the deficiency (CMC vs efficacy/safety).
• Confirm Class 1 (2-month) vs Class 2 (6-month) resubmission.
• Count the total timeline from CRL to decision.
• Check the red flags: third CRL, AdCom no-vote, efficacy-driven.
• Wait for the classification before adding.
• Set your exit before the resubmission PDUFA date.

For the mechanics of the catalyst itself, start with how to trade FDA catalysts. For a second, more recent CRL to compare against, the ITM 177Lu-edotreotide CRL is a useful case study.